Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-014559
Filing Date
2020-05-29
Accepted
2020-05-29 16:32:05
Documents
1
Period of Report
2020-05-27

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7316
  Complete submission text file 0000899243-20-014559.txt   9358
Mailing Address 20 BERKELEY SQUARE LONDON X0 W1J 6EQ
Business Address 20 BERKELEY SQUARE LONDON X0 W1J 6EQ 44(0)20 7290 1050
Arix Bioscience plc (Reporting) CIK: 0001700449 (see all company filings)

State of Incorp.: X0
Type: 4 | Act: 34 | File No.: 001-38800 | Film No.: 20928452

Mailing Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-443-7400
Harpoon Therapeutics, Inc. (Issuer) CIK: 0001708493 (see all company filings)

EIN.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 20 BERKELEY SQUARE LONDON X0 W1J6EQ
Business Address 20 BERKELEY SQUARE LONDON X0 W1J6EQ 44(0)20 7290 1050
Arix Bioscience Holdings Ltd (Reporting) CIK: 0001756884 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38800 | Film No.: 20928451